Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Lydia J Finney, Nicholas Glanville, Hugo Farne, Julia Aniscenko, Peter Fenwick, Samuel V Kemp, Maria-Belen Trujillo-Torralbo, Maria Adelaide Calderazzo, Jadwiga A Wedzicha, Patrick Mallia, Nathan W Bartlett, Sebastian L Johnston, Aran Singanayagam
doi: https://doi.org/10.1101/2020.06.13.149039
Lydia J Finney
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Glanville
2Prokarium, London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo Farne
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Aniscenko
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Fenwick
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel V Kemp
1National Heart and Lung Institute, Imperial College London
3Royal Brompton and Harefield NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria-Belen Trujillo-Torralbo
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Adelaide Calderazzo
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jadwiga A Wedzicha
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Mallia
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan W Bartlett
4Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian L Johnston
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aran Singanayagam
1National Heart and Lung Institute, Imperial College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: a.singanayagam@imperial.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is a new rapidly spreading infectious disease. Early reports of hospitalised COVID-19 cases have shown relatively low frequency of chronic lung diseases such as chronic obstructive pulmonary disease (COPD) but increased risk of adverse outcome. The mechanisms of altered susceptibility to viral acquisition and/or severe disease in at-risk groups are poorly understood. Inhaled corticosteroids (ICS) are widely used in the treatment of COPD but the extent to which these therapies protect or expose patients with a COPD to risk of increased COVID-19 severity is unknown. Here, using a combination of human and animal in vitro and in vivo disease models, we show that ICS administration attenuates pulmonary expression of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme (ACE)-2. This effect was mechanistically driven by suppression of type I interferon as exogenous interferon-β reversed ACE2 downregulation by ICS. Mice deficient in the type I interferon-α/β receptor (Ifnar1−/−) also had reduced expression of ACE2. Collectively, these data suggest that use of ICS therapies in COPD reduces expression of the SARS-CoV-2 entry receptor ACE2 and this effect may thus contribute to altered susceptibility to COVID-19 in patients with COPD.

Competing Interest Statement

S.L.J. has personally received consultancy fees from Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, and Sanofi Pasteura, and Aviragen; he and his institution received consultancy fees from Synairgen, Novarits, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Centocor. S.L.J. is an inventor on patents on the use of inhaled interferons for treatment of exacerbations of airway diseases. M.A.C. was employed by Chiesi Pharmaceuticals from January 2015 to November 2017. A.S. has received honoraria for speaking from AstraZeneca. The remaining authors declare no competing interests.

Footnotes

  • Funding: This work was supported by a Wellcome Trust Clinical Research Training Fellowship to A.S. (grant number WT096382AIA), a Wellcome Trust Seed Award in Science to A.S. (grant number 215275/Z/19/Z), a British Society for Antimicrobial Chemotherapy COVID-19 grant to A.S., a National Institute for Health Research (NIHR) Senior Investigator Award to S.L.J., the NIHR Clinical Lecturer funding scheme (PM) and funding from the Imperial College and NIHR Biomedical Research Centre (BRC) scheme.

  • Conflicts of Interest: S.L.J. has personally received consultancy fees from Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, and Sanofi Pasteura, and Aviragen; he and his institution received consultancy fees from Synairgen, Novarits, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Centocor. S.L.J. is an inventor on patents on the use of inhaled interferons for treatment of exacerbations of airway diseases. M.A.C. was employed by Chiesi Pharmaceuticals from January 2015 to November 2017. A.S. has received honoraria for speaking from AstraZeneca. The remaining authors declare no competing interests.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 15, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
Lydia J Finney, Nicholas Glanville, Hugo Farne, Julia Aniscenko, Peter Fenwick, Samuel V Kemp, Maria-Belen Trujillo-Torralbo, Maria Adelaide Calderazzo, Jadwiga A Wedzicha, Patrick Mallia, Nathan W Bartlett, Sebastian L Johnston, Aran Singanayagam
bioRxiv 2020.06.13.149039; doi: https://doi.org/10.1101/2020.06.13.149039
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
Lydia J Finney, Nicholas Glanville, Hugo Farne, Julia Aniscenko, Peter Fenwick, Samuel V Kemp, Maria-Belen Trujillo-Torralbo, Maria Adelaide Calderazzo, Jadwiga A Wedzicha, Patrick Mallia, Nathan W Bartlett, Sebastian L Johnston, Aran Singanayagam
bioRxiv 2020.06.13.149039; doi: https://doi.org/10.1101/2020.06.13.149039

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4239)
  • Biochemistry (9171)
  • Bioengineering (6804)
  • Bioinformatics (24062)
  • Biophysics (12154)
  • Cancer Biology (9564)
  • Cell Biology (13825)
  • Clinical Trials (138)
  • Developmental Biology (7656)
  • Ecology (11736)
  • Epidemiology (2066)
  • Evolutionary Biology (15540)
  • Genetics (10670)
  • Genomics (14358)
  • Immunology (9511)
  • Microbiology (22901)
  • Molecular Biology (9129)
  • Neuroscience (49112)
  • Paleontology (357)
  • Pathology (1487)
  • Pharmacology and Toxicology (2583)
  • Physiology (3851)
  • Plant Biology (8351)
  • Scientific Communication and Education (1473)
  • Synthetic Biology (2301)
  • Systems Biology (6205)
  • Zoology (1302)